Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate

被引:39
作者
Cruz, DN
Brickel, HM
Wysolmerski, JJ
Gundberg, CG
Simpson, CA
Kliger, AS
Lorber, MI
Basadonna, GP
Friedman, AL
Insogna, KL
Bia, MJ
机构
[1] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA
关键词
alendronate; biphosphonates; bone disease; bone loss; osteoporosis; transplant complication;
D O I
10.1034/j.1600-6143.2002.020111.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Bone mineral density (BMD) and biochemical markers of bone-turnover were evaluated in a 2-year study in 58 long-term renal transplant recipients with good renal function. In the first year of study, data were collected and patients with osteoporosis and parameters of high bone turnover were classified as being at high risk for on-going bone loss (Group A; n = 29). Patients with lesser degrees of bone loss or without biochemical parameters of high bone turnover were followed longitudinally (Group B; n = 29). Group A patients were then placed on alendronate 10 mg/day and both groups were followed for an additional year. Changes in regional BMD and bone-turnover markers between the first and second year within each group were analyzed using paired tests. BMD in Group A, which had declined at the lumbar spine (- 1.6 +/- 0.5%) and total femur (- 1.5 +/- 0.4%) during the first year of the study, increased on alendronate therapy at both the lumbar spine (+ 3.4 +/- 0.6%, p = 0.001) and total femur (+ 1.6 +/- 0.6%, p < 0.001). These patients also experienced a significant decline in levels of serum alkaline phosphatase, osteocalcin, urinary levels of deoxypyridinoline and pyridinoline. In contrast, neither BMD nor biochemical markers changed significantly over 2 years in Group B. The current results demonstrate that renal transplant patients with osteoporosis and biochemical parameters of high bone turnover are at continued risk for bone loss. Therapy with a bisphosphonate can reverse this bone loss and even increase bone mass in these patients. Whether patients with lesser degrees of bone loss and/or patients without parameters of high bone turnover can also benefit from bisphosphonate therapy deserves further study.
引用
收藏
页码:62 / 67
页数:6
相关论文
共 28 条
[1]   HYPERPARATHYROIDISM IS RESPONSIBLE FOR THE INCREASED LEVELS OF OSTEOCALCIN IN PATIENTS WITH NORMALLY FUNCTIONING KIDNEY GRAFTS [J].
AMADO, JA ;
RIANCHO, JA ;
DEFRANCISCO, ALM ;
COTORRUELO, JG ;
FEIJANES, J ;
ARIAS, M ;
NAPAL, J ;
GONZALEZMACIAS, J .
NEPHRON, 1989, 52 (03) :209-215
[2]   Prevention of osteoporosis in heart transplant recipients: A comparison of calcitriol with calcitonin and pamidronate [J].
Bianda, T ;
Linka, A ;
Junga, G ;
Brunner, H ;
Steinert, H ;
Kiowski, W ;
Schmid, C .
CALCIFIED TISSUE INTERNATIONAL, 2000, 67 (02) :116-121
[3]   QUANTITATIVE-ANALYSIS OF THE PYRIDINIUM CROSSLINKS OF COLLAGEN IN URINE USING ION-PAIRED REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
BLACK, D ;
DUNCAN, A ;
ROBINS, SP .
ANALYTICAL BIOCHEMISTRY, 1988, 169 (01) :197-203
[4]   Molecular basis and clinical application of biological markers of bone turnover [J].
Calvo, MS ;
Eyre, DR ;
Gundberg, CM .
ENDOCRINE REVIEWS, 1996, 17 (04) :333-368
[5]   Posttransplant bone disease: Evidence for a high bone resorption state [J].
Cayco, AV ;
Wysolmerski, J ;
Simpson, C ;
Mitnick, MA ;
Gundberg, C ;
Kliger, A ;
Lorber, M ;
Silver, D ;
Basadonna, G ;
Friedman, A ;
Insogna, K ;
Cruz, D ;
Bia, M .
TRANSPLANTATION, 2000, 70 (12) :1722-1728
[6]  
Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO
[7]  
2-K
[8]   Parameters of high bone-turnover predict bone loss in renal transplant patients: A longitudinal study [J].
Cruz, DN ;
Wysolmerski, JJ ;
Brickel, HM ;
Gundberg, CG ;
Simpson, CA ;
Mitnick, MAE ;
Kliger, AS ;
Lorber, MI ;
Basadonna, GP ;
Friedman, AL ;
Insogna, KL ;
Bia, MJ .
TRANSPLANTATION, 2001, 72 (01) :83-88
[9]   Bone loss in long-term renal transplantation: Histopathology and densitometry analysis [J].
Cueto-Manzano, AM ;
Konel, S ;
Hutchison, AJ ;
Crowley, V ;
France, MW ;
Freemont, AJ ;
Adams, JE ;
Mawer, B ;
Gokal, R .
KIDNEY INTERNATIONAL, 1999, 55 (05) :2021-2029
[10]   Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation [J].
Cueto-Manzano, AM ;
Konel, S ;
Freemont, AJ ;
Adams, JE ;
Mawer, B ;
Gokal, R ;
Hutchison, AJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (02) :227-236